Kornimate/medical-research-clean huggingface dataset:
hope-genomics intervention for the improvement of cancer patient knowledge of genomics

Conditions: Breast Carcinoma; Colorectal Carcinoma; Lung Carcinoma; Malignant Solid Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Carcinoma

Summary: this clinical trial studies the effectiveness of a web-based cancer education tool called helping oncology patients explore genomics (hope-genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. hope-genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. the hope-genomics tool may improve patient's genomic knowledge and quality of patient-centered care. in addition, it may also improve education and care quality for future patients.

primary objectives: i. test the efficacy of the hope-genomics intervention in improving patient knowledge of genomics. ii. test the efficacy of the hope-genomics intervention in improving patient receipt of guideline-concordant care. outline: patients are randomized to 1 of 3 arms. arm i (usual care): patients receive education pamphlet about whole-genome sequencing (wes) and have their genomics test results returned by their clinician in a typical manner. arm ii (return of results only): patients receive their genomics test results both from their clinician and from the hope-genomics tool. patients then view hope-genomics tool over 15-20 minutes after their results are available. arm iii (return of results plus pre-test education): patients view hope-genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. patients also receive their genomics test results both from their clinician and from the hope-genomics tool. after completion of study intervention, patients are followed up at 2 weeks, 3 and 9 months after receiving genomic test results.

Eligibility criteria:
inclusion criteria: * are enrolled in city of hope (coh) institutional review board (irb) 07047 * have a diagnosis of lung, breast, colorectal, pancreatic, ovarian or prostate cancer * having somatic, germline or paired somatic/germline sequencing * are fluent in english * have an eastern cooperative oncology group (ecog) performance status of 0-2 * are \>= 18 years old exclusion criteria: * are unable to provide informed consent
use of antithrombin in cardiac surgery with cardiopulmonary bypass

Conditions: Acquired Antithrombin III Deficiency; Coronary Artery Bypass

Summary: the purpose of this trial is to study the effects of preoperative antithrombin supplementation in patients undergoing cardiac surgery with cardiopulmonary bypass in order to maintain antithrombin levels in a range greater than 58% of functional activity and, eventually, to decrease negative clinical outcomes during the icu stay.


Eligibility criteria:
inclusion criteria: * male or female * at least 18 years of age * subject needed elective cardiac surgery with cardiopulmonary bypass except for heart transplantation * subject had a baseline atiii level of less than 100% and equal to or above 60% * subject signed the informed consent form * subject was willing to comply with all aspects of the protocol, including blood sampling, for the total duration of the study exclusion criteria: * documented congenital atiii deficiency or atiii levels below 60% * subject had a baseline atiii level of 100% or higher * subject needed emergency (non-elective) surgery * subject needed heart transplantation * history of anaphylactic reaction(s) to blood or blood components * allergies to excipients * subject was pregnant * subject had any medical condition that according to the investigators judgment worsens the surgical outcome above the expected * subject had any medical condition which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the trial according to the investigators judgment * subject had participated in any another investigational study within the last 30 days previous to the inclusion

Keywords: antithrombin atiii acquired deficiency anticoagulants cardiopulmonary bypass surgery complications postoperative outcomes
strategies to increase hiv testing, linkages to care, and male circumcision in africa

Conditions: HIV

Summary: the purpose of this study is to determine efficient, scalable, evidence-based strategies to link hiv positive individuals to care and hiv negative individuals to prevention measures, such as voluntary male circumcision.

new strategies for hiv testing and linkages to care are needed, since only a minority of african adults have been tested in many settings and a drop-off occurs at each step from hiv and cd4 testing, remaining in pre-art (antiretroviral therapy) care, art initiation, and adherence over the long term. this study aims to determine the effects of point-of-care (poc) cd4 testing, poc viral load (vl) testing and several linkage strategies (lay-counselor follow-up, accompaniment to hiv clinic by lay counselor, or clinical referral) on linkage to care and treatment adherence for hiv positive persons. this study also aims to determine the uptake of voluntary circumcision among hiv uninfected males with either promotion at point of hiv testing, short message service (sms) follow-up or lay counselor follow-up visits.

Eligibility criteria:
inclusion criteria: * reside in the study community * must be 16 years or older * able and willing to provide informed consent/assent for study procedures * hiv negative uncircumcised men must be age 16 - 49 years and have access to secure text messaging to be randomized to strategies for male circumcision. exclusion criteria: * n/a

Keywords: hiv hiv counseling and testing linkages to care point of care cd4 point of care viral load
h.o.p.e: helping ovarian cancer patients cope

Conditions: Platinum-resistant Ovarian Cancer; Recurrent Ovarian Cancer; Palliative Care

Summary: the purpose of this study is to test the effect of the gynecologic oncologists with palliative care specialist collaboration (go-pc) intervention on patient quality of life.

eligible patients include women diagnosed with platinum-resistant ovarian cancer or recurrent ovarian cancer cancer. all patient participants will complete two quality of life (qol) questionnaires and a cost-diary documenting their health care experience at time of consent and every 12 weeks thereafter. consenting care givers will also be asked to complete two questionnaires to asses the impact of structured palliative care on them every 12 weeks. patients will be assigned to two arms randomly: 1) usual care or 2) structured palliative care. the primary endpoint is quality of life. a two-sided chi-square test will be used to compare the proportion of patients who have improved quality of life after treatment between control arm and intervention arm. the average value of multiple scores after treatment will be used to compare with the baseline score before treatment for each question in the standard questionnaire.

Eligibility criteria:
inclusion criteria: * platinum-resistant ovarian cancer or recurrent ovarian cancer * ability to read and respond to questions in english exclusion criteria: * platinum-sensitive recurrent ovarian cancer without a significant clinical event * existence of co-morbid disease, which in the opinion of the investigator prohibits participation in the protocol
effect of an antiseptic solution on the skin microbiome

Conditions: Skin Diseases, Infectious

Summary: the objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.


Eligibility criteria:
inclusion criteria: a subject may be eligible for study participation if all of the following criteria are met: 1. subject is male or female greater than 18 years of age. 2. subject does not have a history of skin allergies/atopia (e.g. atopic dermatitis). 3. subject does not have a history of skin disease (e.g scleroderma, vitiligo, psoriasis) or a chronic systemic disease affecting the skin (e.g systemic lupus erythematosus). 4. subject is willing to have materials applied and follow the protocol. 5. subject agrees to avoid exposure of the test sites to the sun, chemical product, clothes and to refrain from touching the area of application (for t0 \[baseline\], t1 \[5 minutes\], t2 \[2 hours\]). 6. subject agrees to refrain from getting a bath/shower before t3 (24 h). 7. subject agrees to avoid scrubbing, applying, and/or washing the test area with new soap, moistures, powders, lotions, cosmetic or toiletry products during the study. 8. subject is able to follow directions as outlined in the protocol and anticipates being available for all study visits. 9. subject is willing to participate in all study evaluations. 10. subject is in generally good health. 11. subject is willing to sign the informed consent form prior to study participation exclusion criteria: 1. female subject is pregnant, nursing, planning a pregnancy, or not using adequate birth control. 2. subject is immunologically compromised or has received specific topical treatment (antimicrobial or not-antimicrobial), during the last month. 3. subject reports a history of allergies to antiseptics. 4. subject is currently taking certain medications which, in the opinion of the principal investigator, may interfere with the study. 5. subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs.
non-adhesive liquid embolic system in the embolization of cerebral arteriovenous malformations

Conditions: Intracranial Arteriovenous Malformations

Summary: this clinical trial is to verify the safety and effectiveness of the non-adhesive liquid embolic system(nales) produced by suzhou hengrui hongyuan medical technology co., ltd. in the process of clinical use to support the application of the national medical products administration ( nmpa) product registration approval.

a prospective, multicenter, randomized controlled trial was used in this study. onyx liquid embolic system and marathon flow directed micro catheter, which were registered and marketed in china and had good effect in the industry, were selected as the control devices. subjects requiring cerebral arteriovenous malformation embolization were selected to participate in the trial based on pathological conditions and inclusion/exclusion criteria, and the use of test products or control products was determined based on central randomized results. imaging data involving the main evaluation criteria were evaluated uniformly by the blind evaluators of the leading unit, so as to reduce the bias caused by subjective factors of different evaluators.

Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, no gender limit. 2. the patient was diagnosed as cerebral arteriovenous malformation . 3. the patient had no history of bavm treatment, including intervention, surgery or radiotherapy . 4. spetzler martin, grade i-iv . 5. the patient voluntarily signed the informed consent. exclusion criteria: 1. history of heparin allergy. 2. the patient is allergic to contrast media. 3. severe hepatic and renal insufficiency (serum creatinine ≥1.5 times the upper limit of normal value, alanine aminotransferase ≥3 times the upper limit of normal value, aspartate aminotransferase ≥3 times the upper limit of normal value). 4. patient has irreversible coagulopathy (inr \> 1.5). 5. intracranial hemorrhage 1 week before treatment. 6. mrs ≥4 due to neurological dysfunction. 7. patients with planned malformation resection after embolization. 8. blood flow related aneurysms of supplying artery that need to be treated by other methods. 9. complicated with severe cerebral artery stenosis. 10. brain tumors that require recent surgery. 11. complicated with proliferative cerebrovascular disease. 12. pregnant or lactating women. 13. participants who have participated in other clinical trials within the last 3 months and failed to reach the end point. 14. the number of embolism is expected to be greater than or equal to 4 times during the study period (within 1 year). 15. subjects deemed unsuitable for this study by the investigator.

Keywords: non-adhesive liquid embolic system
traditional african healing ceremony in a u.s. population

Conditions: Chronic Fatigue Syndrome; Anxiety; Depression; Cancer

Summary: pre-agricultural societies almost universally used healing ceremonies that involved reverence, rhythm and dance in the presence of a healer. it is believed that we are "wired" for such experiences and they foster an integrative mode of consciousness similar to that of mindfulness based stress reduction, which has been shown to have therapeutic effects in a variety of conditions. collaborator ava lavonne vinesett of the duke dance program has developed a healing ceremony based in sub-saharan african traditions. the investigators plan is to have 25 subjects with a variety of clinical conditions participate in this ceremony. subjects will then be asked to write a commentary about their experience and to participate in a focus group discussion. it is anticipated that the study will give us some idea of how promising this approach would be and what kinds of patients might benefit. safety issues are minimal and include the possibility of injury (though the dancing is not strenuous) and psychological distress.


Eligibility criteria:
inclusion criteria: * age 25 to 65 with one of the diagnoses listed above or with 8 visits to their provider in the last year and with no diagnosis of chronic illness. exclusion criteria: * physical disability making participation difficult and previous experience with a similar ceremony, for instance while growing up in africa.
treatment of intractable common extensor tendon injury using mesenchymal stem cells (allo-asc)

Conditions: Lateral Epicondylitis

Summary: the aim of this study is to evaluate the efficacy and safety of intra-tendon injection of allogeneic adipose-derived mesenchymal stem cells (allo-asc) in intractable common extensor tendinosis patients in comparison with a control treatment.

a phase ii randomized placebo controlled trial will be done with following 3 groups. each group will have 10 participants, so, the total patients will be 30 people. 1. high concentration of allo-asc group: stem cell 0.5cc (total: 10 million cells) + fibrin glue 0.5cc 2. low concentration of allo-asc group: stem cell 0.5cc (total: 1 million cells) + fibrin glue 0.5cc 3. placebo comparator (fibrin) group: normal saline 0.5cc + fibrin glue 0.5cc the investigators will compare the efficacy difference with visual analogue scale (vas) during activity (primary outcome), vas at rest, mayo elbow performance index (mepi), grip strength, ultrasonographic assessment at baseline, 6 weeks, 12 weeks, 6 months, 12 months and 24 months after injection. shear wave elastography (swe) and magnetic resonance image (mri) will be done at baseline, 12 weeks, 12 months and 24 months after injection

Eligibility criteria:
inclusion criteria: * clinically diagnosed as lateral epicondylosis (tennis elbow) * symptom duration is over 12 months * pain visual analogue scale (vas) during activity ≥ 5 * recurrent pain in spite of conservative treatment such as physical therapy, medication, steroid injection * common extensor tendon injury can be observed under ultrasound (hypoechoic lesion) and mri (hyperintensity or discontinuity) * patient that can understand the clinical trials exclusion criteria: * patient that underwent other injection such as steroid injection or prolotherapy within 6 weeks * patients with following conditions (such as arthritis related to the target lesion, synovitis related to the target lesion, paralysis related to the target lesion, entrapment of related nerve to the target lesion, radiculopathy related to the target lesion, infectious disease, generalized pain syndrome, rheumatoid arthritis, impaired sensibility, dementia, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue, contraindication to mri) * patient that enrolled other clinical trials within 30 days * current pregnancy or breast-feeding, planning for pregnancy * history of drug/alcohol addiction, habitual smoker * operation history of affected elbow * previous clinical trial involving stem cell administration * other severe medical illness or bleeding tendency * size of intramural calcification over 2.0 mm under ultrasound evaluation

Keywords: adipose derived mesenchymal stem cell allogeneic stem cell
prehospital triage of patients with severe shortness of breath using biomarkers

Conditions: Dyspnea

Summary: breathlessness is a dangerous symptom. preliminary data from national and regional danish databases show, that patients with shortness of breath in the ambulance have a very high mortality. breathlessness can be caused by many different conditions - but heart diseases and lung diseases are dominant. the mortality is especially high in patients with breathlessness caused by heart disease. distinguishing these different causes of breathlessness is a classical, often difficult, discipline in medicine. visitation and guidance of treatment in patients with breathlessness in the prehospital setting relies on medical history and physical examination and as a consequence prehospital treatment for breathlessness is often non-specific. the use of heart-failure specific biomarkers may improve prehospital visitation and treatment of patients with breathlessness. we hypothesize, that 1. supplementing the routine examination by prehospital anesthesiologist with measurement of a biomarker for heart failure increases the proportion of patients with severe shortness of breath caused by heart disease triaged directly to department of cardiology 2. this strategy does not increase the proportion of patients with severe shortness of breath caused by non-heart disease triaged directly to department of cardiology

measurement of the biomarker for heart failure n-terminal pro-brain natriuretic peptide (nt-probnp): in patients randomized to the strategy with supplementary measurement of nt-probnp, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted. this will be analyzed point-of-care in the ambulance. interpretation of nt-probnp: cut-off values based on bootstrap-validated optimal cut-points for heart failure on will be used. confirmatory ('rule in') cut point \< 50 years: 450 pg/ml 50-75 years: 900 pg/ml \> 75 years: 1800 pg/ml exclusionary ('rule out') cut point all patients: 300 pg/ml the emergency physicians will be thoroughly informed about these cut-points, but told not to triage to department of cardiology or other department strictly according to nt-probnp, but according to clinical assessment and nt-probnp.

Eligibility criteria:
inclusion criteria: all patients requiring dispatch of emergency physician because of severe dyspnea. severe dyspnea is defined by dyspnea plus at least one of the following * respiration frequency \> 20 or \< 8 * saturation \< 96 without supplementary oxygen * heart rate \> 100 or \< 50 * systolic blood pressure \ 200 * difficulty talking * central or peripheral cyanosis * use of accessory muscles of respiration * glasgow coma scale score \< 15 and because of the physical condition, the patient is not able to give informed consent exclusion criteria age \< 18

Keywords: dyspnea prehospital biomarker heart failure triage randomized, controlled study
post marketing surveillance study of cuprimine

Conditions: Scleroderma

Summary: cuprimine (penicillamine) was made available in the philippines by the sponsor under a compassionate special permit issued by the bureau of food and drugs. physicians were able to request the drug for their patients from the sponsor. a clinical study report form was completed for each purchase of cuprimine.


Eligibility criteria:
inclusion criteria: - none exclusion criteria: - none
effect of glp-1 analogs on psoriasis in type 2 diabetic patients

Conditions: Type 2 Diabetes; Psoriasis

Summary: the aim of the study is to evaluate after 4 to 6 months the effects of a glp-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.

the objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a glp-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments. exclusion criteria: * type 1 diabetes * secondary diabetes * liver, renal or pancreatic disease * previous treatment with glp-1 agonist or dpp-4 inhibitors agents

Keywords: type 2 diabetes psoriasis exenatide liraglutide
living donor liver transplantation in children

Conditions: Pediatric Liver Transplanted Recipients; Healthy Donors

Summary: evaluate the outcome of pediatric living donor liver transplantation (ldlt) regarding portal vein reconstruction, abo-compatibility and impact of maternal donation on graft acceptance.

data from 250 pediatric ldlt recipients (and their donors), transplanted at cliniques universitaires saint-luc between july 1993 and june 2012, were collected retrospectively using electronic data files. results were analysed according to abo matching and portal vein complications. uni- and multi-variate analysis was used to study the impact of immunosuppression, gender match and maternal donation on acute rejection rate.

Eligibility criteria:
inclusion criteria: * children receiving a living donor liver transplant * adult living donors exclusion criteria: * no one

Keywords: liver failure liver malignancy metabolic diseases pediatric liver transplanted recipients and their healthy donors
surgical outcome and predictors of overall survival of stage i-iii appendiceal adenocarcinoma

Conditions: Appendiceal Cancer

Summary: a few studies investigated the predictors of overall survival in appendiceal adenocarcinoma. a seer database analysis of 1404 patients with appendiceal adenocarcinoma found that older age, t4 tumors, n1-2 stage, poorly differentiated carcinoma, and distant metastasis were significantly predictive of poorer survival. another small single-center study including 49 appendiceal cancer patients reported female gender and low-grade adenocarcinoma to be associated with increased overall survival. however, these previous analyses did not take into account some important prognosticators of survival such as patients' comorbidities and functional status, pathologic parameters such as lymphovascular invasion, and adjuvant systemic treatment. therefore, we used the national cancer database (ncdb) to conduct a comprehensive analysis of the predictors of overall survival after surgical treatment of stage i-iii appendiceal adenocarcinoma.


Eligibility criteria:
inclusion criteria: * patients with non-metastatic appendiceal adenocarcinoma who underwent surgical resection exclusion criteria: * patients with other pathologic types of appendiceal cancer * patients with clinical stage iv or unknown stage * patients who did not undergo surgery, underwent local excision, or had unknown/non-specified surgery